The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Jorge Cortes from MD Anderson Cancer Center (MDACC), Houston, TX, and colleagues reported data from a randomized phase IIb study (NCT01565668), which is assessing the safety and efficacy of two quizartinib (an oral, highly potent and selective FLT3 inhibitor) dosing regimens in patients with relapsed /refractory (R/R) FLT3-internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia (AML) who previously underwent hematopoietic stem cell transplantation (HSCT) or received one second-line salvage therapy. The results of the study were reported in Blood in June 2018.1
In previous clinical studies, quizartinib has demonstrated promising clinical activity in patients with R/R AML, however, QT interval corrected by Fridericia's formula (QTcF) was a dose-limiting toxicity. The main objective of this phase IIb study was to determine whether different doses of quizartinib would have the same clinical activity while improving the safety in patients with R/R FLT3-mutated AML. Between May 2012 and March 2015, 76 patients (median age = 55 years, range 19–77) were enrolled and randomized to receive either 30 mg/day (n = 38) or 60 mg/day (n = 38) quizartinib.
The primary endpoints of the study were composite complete remission (CRc) rate and the incidence of grade ≥ 2 QTcF.
In summary, the findings of this randomized phase IIb study demonstrated encouraging anti-leukemic activity and an improved safety profile particularly in terms of QTcF prolongation, according to the researchers. Moreover, compared to quizartinib at 30 mg/day, quizartinib at 60-mg/day was associated with higher CRc rate, OS, and more patients were bridged to transplant in this arm. Key limitations of this study include the trial design and the small sample size.
The researchers concluded that the benefit-risk profile of quizartinib in R/R FLT3-ITD-mutated AML warrants further evaluation of the 60-mg once daily dose which is currently being investigated in the phase III randomized QuANTUM-R study (NCT02039726). The phase III study is assessing the efficacy and safety of quizartinib (60 mg, with a 30 mg lead-in for 15 days) versus salvage chemotherapy in patients with R/R FLT3-ITD-mut AML. Data from this study presented at the 23rd Congress of the European Hematology Association, Stockholm, Sweden, demonstrated that quizartinib significantly prolongs OS in R/R FLT3-ITD AML patients compared to salvage chemotherapy. More results from this study were reported here.2
References